e-learning
resources
ERJ
2016
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD
Magnussen Helgo, Tetzlaff Kay, Bateman Eric D., Watz Henrik, Kirsten Anne M., Wouters Emiel F.M., Disse Bernd, Finnigan Helen, Rodriguez-Roisin Roberto, Calverley Peter M.A.
Source:
Eur Respir J 2016; 47: 651-654
Journal Issue:
February
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Magnussen Helgo, Tetzlaff Kay, Bateman Eric D., Watz Henrik, Kirsten Anne M., Wouters Emiel F.M., Disse Bernd, Finnigan Helen, Rodriguez-Roisin Roberto, Calverley Peter M.A.. Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD. Eur Respir J 2016; 47: 651-654
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Evaluation of the individual bronchodilator response in patients with severe COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 246s
Year: 2002
Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids
Source: Eur Respir J, 49 (6) 1700848; 10.1183/13993003.00848-2017
Year: 2017
Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids
Source: Eur Respir J 2017; 49(1): 1600839; DOI: 10.1183/13993003.00839-2016
Year: 2017
Withdrawal of inhaled corticosteroids in COPD patients with mild or moderate airflow limitation: who is suitable for a trial of withdrawal?
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019
Pulmonary function test changes after cessation of inhaled corticosteroid therapy in asthma patients
Source: Annual Congress 2012 - Aspects of clinical asthma
Year: 2012
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment
Source: Eur Respir J 2006; 27: 964-971
Year: 2006
Severe exacerbations, decline in lung function and inhaled budesonide in asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 619s
Year: 2007
Inhaled corticosteroids and the risk of a first exacerbation in COPD patients
Source: Eur Respir J 2004; 23: 692-697
Year: 2004
Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Are inhaled corticosteroids increasing the “load” for some patients with COPD?
Source: Eur Respir J, 50 (4) 1701848; 10.1183/13993003.01848-2017
Year: 2017
The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD
Source: Eur Respir J, 54 (6) 1900521; 10.1183/13993003.00521-2019
Year: 2019
Assessment of maximal airway response before and after inhaled corticosteriod treatment in new diagnosed asthma patients
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007
Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids
Source: International Congress 2016 – New findings in mucosal immunology
Year: 2016
ERS guideline on withdrawal of inhaled corticosteroids in COPD
Source: ERS webinar 2021: ERS guideline on withdrawal of inhaled corticosteroids in COPD
Year: 2021
Acute and chronic effects of inhaled bronchodilators in patients with 'irreversible' COPD at rest and during exercise
Source: Eur Respir J 2002; 20: Suppl. 38, 302s
Year: 2002
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation
Source: Eur Respir J 2001; 18: Suppl. 33, 261s
Year: 2001
Lung function, symptoms and prescription of inhaled steroids and long acting β2 agonists in patients managed by an integrated COPD team
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Withdrawal of high-dose inhaled corticosteroids in COPD patients with mild or moderate airflow limitation: a feasibility study in primary care.
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept